36M Stock Overview A medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Shockwave Medical, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Shockwave Medical Historical stock prices Current Share Price US$307.70 52 Week High US$307.70 52 Week Low US$145.45 Beta 0.88 1 Month Change 0.098% 3 Month Change 28.69% 1 Year Change 18.57% 3 Year Change 121.37% 5 Year Change n/a Change since IPO 673.12%
Recent News & Updates
Shockwave Medical Unveils First Clinical Outcomes of New IVL Platform in Late-Breaking Presentation at VIVA 2024 Nov 05
Shockwave Medical, Inc. Announces U.S. Launch of the Shockwave E8 Peripheral Ivl Catheter Sep 16
Shockwave Medical Files Form 15 Jun 13 Shockwave's Common Stock Ceases Trading on NASDAQ Jun 05
Shockwave Medical, Inc. Announces Termination of Employment of Renee Gaeta as Chief Financial Officer Johnson & Johnson (NYSE:JNJ) completed the acquisition of Shockwave Medical, Inc. (NasdaqGS:SWAV) from a group of sellers. Jun 01
See more updates
Shockwave Medical Unveils First Clinical Outcomes of New IVL Platform in Late-Breaking Presentation at VIVA 2024 Nov 05
Shockwave Medical, Inc. Announces U.S. Launch of the Shockwave E8 Peripheral Ivl Catheter Sep 16
Shockwave Medical Files Form 15 Jun 13 Shockwave's Common Stock Ceases Trading on NASDAQ Jun 05
Shockwave Medical, Inc. Announces Termination of Employment of Renee Gaeta as Chief Financial Officer Johnson & Johnson (NYSE:JNJ) completed the acquisition of Shockwave Medical, Inc. (NasdaqGS:SWAV) from a group of sellers. Jun 01
Shockwave Medical Withdraws Earnings Guidance for the Full Year 2024 May 08
First quarter 2024 earnings released: EPS: US$1.48 (vs US$1.07 in 1Q 2023) May 07
Shockwave Medical, Inc., Annual General Meeting, May 29, 2024 May 01
Shockwave Medical, Inc. Announces Investigators Presented Six-Month Data from the Full Population of the Reducer-I Study Apr 09
Johnson & Johnson (NYSE:JNJ) entered into a definitive agreement to acquire Shockwave Medical, Inc. (NasdaqGS:SWAV) for $13 billion. Apr 07 Johnson & Johnson (NYSE:JNJ) entered into a definitive agreement to acquire Shockwave Medical, Inc. (NasdaqGS:SWAV) for $13 billion. Apr 06
Insufficient new directors Apr 01 Johnson & Johnson Reportedly Considers Deal for Shockwave Medical Mar 28
Now 21% undervalued Mar 26
New minor risk - Shareholder dilution Feb 27
Independent Director recently sold €14m worth of stock Feb 25
Shockwave Medical, Inc. Provides Earnings Guidance for 2024 Feb 16
Full year 2023 earnings released: EPS: US$4.01 (vs US$6.02 in FY 2022) Feb 16
Shockwave Medical, Inc. Appoints Renee Gaeta as Chief Financial Officer, Effective February 5, 2024 Jan 29 Shockwave Medical, Inc. to Report Q3, 2024 Results on Nov 04, 2024
Now 21% undervalued after recent price drop Dec 06
Investor sentiment deteriorates as stock falls 27% Nov 13
Shockwave Medical, Inc. Announces New Data Demonstrating One-Year Outcomes with Coronary Lithotripsy Nov 10
Shockwave Medical, Inc. Provides Revenue Guidance for the Full Year 2023 Nov 08
Now 22% undervalued after recent price drop Nov 08
Third quarter 2023 earnings released: EPS: US$0.95 (vs US$0.97 in 3Q 2022) Nov 07
Shockwave Medical, Inc. Introduces Enhanced Coronary IVL Catheter in the United States Oct 23
Shockwave Medical, Inc. Announces New Shockwave Coronary IVL Publications Confirm Safety and Efficacy Across Multiple Calcium Morphologies Oct 20
Shockwave Medical, Inc. Appoints Nick West as Associate Chief Medical Officer Sep 14 Daniel K. Puckett Notifies Shockwave Medical, Inc. of His Intention to Retire as Chief Financial Officer Sep 12
New minor risk - Shareholder dilution Aug 09
Shockwave Medical, Inc. Revises Revenue Guidance for the Full Year 2023 Aug 09
Second quarter 2023 earnings released: EPS: US$0.79 (vs US$0.71 in 2Q 2022) Aug 08
Shockwave Medical, Inc.(NasdaqGS:SWAV) dropped from Russell 2000 Dynamic Index Jun 25
Shockwave Medical, Inc. Appoints Kevin Ballinger to Board of Directors and Will Serve on Shockwave’s Nominating and ESG Committee and the Compensation Committee of the Board May 18
Key Executive recently sold €548k worth of stock May 15 Shockwave Medical Reportedly Picks Up Takeover Interest from Two Additional Suitors May 13
Shockwave Medical Reportedly Picks Up Takeover Interest from Two Additional Suitors May 12
First quarter 2023 earnings released: EPS: US$1.07 (vs US$0.41 in 1Q 2022) May 09
Shockwave Medical, Inc. Revises Revenue Guidance for the Year 2023 May 09
Investor sentiment improves as stock rises 15% Apr 17
Independent Director recently sold €132k worth of stock Feb 27
Shockwave Medical, Inc. Provides Earnings Guidance for the Full Year 2023 Feb 18
Full year 2022 earnings released: EPS: US$6.02 (vs US$0.26 loss in FY 2021) Feb 18
ShockWave Medical, Inc. (NasdaqGS:SWAV) entered into a definitive agreement to acquire Neovasc Inc. (TSX:NVCN) from Strul Medical Group LLC and others for $75.04 million. Jan 19
ShockWave Medical, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2022 and Fiscal Year 2023 Jan 18 ShockWave Medical, Inc. to Report Q4, 2022 Results on Feb 16, 2023
Now 23% undervalued after recent price drop Dec 13
Third quarter 2022 earnings released: EPS: US$0.97 (vs US$0.055 in 3Q 2021) Nov 09 ShockWave Medical, Inc. Revises Revenue Guidance for the Year 2022 Nov 08
ShockWave Medical, Inc. Confirms Consistent Outcomes for IVL in the larger Prospective “Real World” Study of Patients with Heavily Calcified Peripheral Arterial Disease Nov 03
Independent Director recently sold €192k worth of stock Sep 11
Chief Accounting Officer recently sold €1.1m worth of stock Aug 31
ShockWave Medical, Inc. Revises Revenue Guidance for the Full Year 2022 Aug 09
Second quarter 2022 earnings released: EPS: US$0.71 (vs US$0.012 loss in 2Q 2021) Aug 09
Shockwave Medical, Inc. and Genesis MedTech Group Successfully Obtains Approval from China’S National Medical Products Administration to Market and Sell the Shockwave IVL System with the Shockwave C2 Coronary IVL Catheters and the Shockwave M5 and S4 Peripheral IVL Catheters in China May 24 Shockwave Ivl Maintains Superiority to Angioplasty in Calcified Peripheral Disease At Two Years
First quarter 2022 earnings released: EPS: US$0.41 (vs US$0.68 loss in 1Q 2021) May 11 ShockWave Medical, Inc. Revised Earnings Guidance for the Full Year 2022 May 10
ShockWave Medical, Inc., Annual General Meeting, Jun 23, 2022 May 02
Independent Director recently sold €357k worth of stock Apr 02
Shockwave Medical, Inc. Announces the Global Commercial Availability of the Shockwave M5+ Peripheral IVL Catheter After Receiving Both CE Mark and U.S. Food and Drug Administration Clearance Apr 01
Shockwave Medical Announces Japanese Regulatory Approval of Coronary IVL Mar 31
Key Executive recently sold €760k worth of stock Feb 25
ShockWave Medical, Inc. Announces Executive Changes Feb 24 Shareholder Returns 36M DE Medical Equipment DE Market 7D 0.4% -2.9% -2.6% 1Y 18.6% -8.5% 6.9%
See full shareholder returns
Return vs Market: 36M exceeded the German Market which returned 3% over the past year.
Price Volatility Is 36M's price volatile compared to industry and market? 36M volatility 36M Average Weekly Movement 4.6% Medical Equipment Industry Average Movement 6.6% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.2% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 36M's share price has been volatile over the past 3 months.
Volatility Over Time: 36M's weekly volatility (5%) has been stable over the past year.
About the Company Shockwave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels. It also provides product for the treatment of coronary artery disease, such as C2 IVL catheter and C2+IVL catheter that are two-emitter catheters for use in IVL system; and Reducer, a device to treat refractory angina.
Show more Shockwave Medical, Inc. Fundamentals Summary How do Shockwave Medical's earnings and revenue compare to its market cap? 36M fundamental statistics Market cap €11.58b Earnings (TTM ) €150.70m Revenue (TTM ) €726.27m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 36M income statement (TTM ) Revenue US$787.97m Cost of Revenue US$102.53m Gross Profit US$685.44m Other Expenses US$521.94m Earnings US$163.50m
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 05, 2024
Earnings per share (EPS) 4.35 Gross Margin 86.99% Net Profit Margin 20.75% Debt/Equity Ratio 97.5%
How did 36M perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/05/31 23:26 End of Day Share Price 2024/05/31 00:00 Earnings 2024/03/31 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Shockwave Medical, Inc. is covered by 12 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Travis Steed BofA Global Research William Plovanic Canaccord Genuity Kristen Stewart CL King & Associates, Inc.
Show 9 more analysts 
